Sichuan Kelun Pharmaceutical Co Ltd Total Liabilities
Sichuan Kelun Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Sichuan Kelun Pharmaceutical Co Ltd (002422) has total liabilities worth CN¥11.66 Billion CNY (≈ $1.71 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Sichuan Kelun Pharmaceutical Co Ltd (002422) liquidity interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Sichuan Kelun Pharmaceutical Co Ltd (2007–2025)
Total liabilities of Sichuan Kelun Pharmaceutical Co Ltd from 2007 to 2025. This chart illustrates how Sichuan Kelun Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Sichuan Kelun Pharmaceutical Co Ltd (002422) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Sichuan Kelun Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Sichuan Kelun Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Merchants Shekou Industrial Zone Holdings
SHE:001979
|
China | CN¥589.81 Billion |
|
Universal Health Services Inc
NYSE:UHS
|
USA | $8.11 Billion |
|
Shenzhen Transsion Holdings Co Ltd
SHG:688036
|
China | CN¥26.32 Billion |
|
Bentley Systems Inc
NASDAQ:BSY
|
USA | $2.30 Billion |
|
WISE PLC SPONS.ADR/1
F:6WS0
|
Germany | €17.86 Billion |
|
Topbuild Corp
NYSE:BLD
|
USA | $4.31 Billion |
|
Maplebear Inc.
NASDAQ:CART
|
USA | $941.00 Million |
|
American Healthcare REIT, Inc.
NYSE:AHR
|
USA | $2.08 Trillion |
Liability Composition Analysis (2007–2025)
This chart breaks down Sichuan Kelun Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Sichuan Kelun Pharmaceutical Co Ltd total assets.
Liquidity & Leverage Metrics
Sichuan Kelun Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Sichuan Kelun Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sichuan Kelun Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sichuan Kelun Pharmaceutical Co Ltd (2007–2025)
The table below shows the annual total liabilities of Sichuan Kelun Pharmaceutical Co Ltd from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥10.54 Billion ≈ $1.54 Billion |
-0.35% |
| 2024-12-31 | CN¥10.58 Billion ≈ $1.55 Billion |
-21.29% |
| 2023-12-31 | CN¥13.44 Billion ≈ $1.97 Billion |
-22.47% |
| 2022-12-31 | CN¥17.33 Billion ≈ $2.54 Billion |
-0.43% |
| 2021-12-31 | CN¥17.41 Billion ≈ $2.55 Billion |
-3.31% |
| 2020-12-31 | CN¥18.01 Billion ≈ $2.63 Billion |
+2.43% |
| 2019-12-31 | CN¥17.58 Billion ≈ $2.57 Billion |
+7.21% |
| 2018-12-31 | CN¥16.40 Billion ≈ $2.40 Billion |
+2.44% |
| 2017-12-31 | CN¥16.01 Billion ≈ $2.34 Billion |
+34.01% |
| 2016-12-31 | CN¥11.94 Billion ≈ $1.75 Billion |
+4.59% |
| 2015-12-31 | CN¥11.42 Billion ≈ $1.67 Billion |
+11.60% |
| 2014-12-31 | CN¥10.23 Billion ≈ $1.50 Billion |
+29.15% |
| 2013-12-31 | CN¥7.92 Billion ≈ $1.16 Billion |
+35.05% |
| 2012-12-31 | CN¥5.87 Billion ≈ $858.48 Million |
+131.48% |
| 2011-12-31 | CN¥2.53 Billion ≈ $370.86 Million |
+43.16% |
| 2010-12-31 | CN¥1.77 Billion ≈ $259.05 Million |
+0.93% |
| 2009-12-31 | CN¥1.75 Billion ≈ $256.66 Million |
+19.65% |
| 2008-12-31 | CN¥1.47 Billion ≈ $214.51 Million |
+33.75% |
| 2007-12-31 | CN¥1.10 Billion ≈ $160.38 Million |
-- |
About Sichuan Kelun Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, ve… Read more